Hiệu quả điều trị vảy phấn trắng ở mặt bằng bôi Tacrolimus 0,03% tại Bệnh viện Da liễu Trung ương

Pityriasis alba is a prevalent dermatological condition, particularly affecting children and adolescents, characterized by hypopigmented lesions on the face. While generally benign and self-limiting, its visible aesthetic impact often leads to significant psychological distress and reduced quality of life for affected individuals, especially in school-aged children. Effective and safe treatment options are crucial for managing this condition. Topical Tacrolimus 0.03% has emerged as a promising alternative to traditional corticosteroids, known for its efficacy in treating inflammatory skin conditions and its favorable safety profile in sensitive areas. This study therefore aims to evaluate the clinical outcomes of using topical Tacrolimus 0.03% in the treatment of facial pityriasis alba at the National Hospital of Dermatology and Venereology, providing valuable local data on its effectiveness and tolerability.

Dermatologists, pediatricians, general practitioners, and clinical researchers interested in the management of dermatological conditions, particularly pityriasis alba, and the use of topical immunomodulators.

This clinical trial investigated the efficacy and safety of topical Tacrolimus 0.03% compared to Desonide 0.05% for treating facial pityriasis alba. Conducted over 8 weeks at the National Hospital of Dermatology and Venereology, the study enrolled 60 patients, randomly assigning 30 to the Tacrolimus group and 30 to the Desonide group. Researchers assessed changes in pigmentation index, lesion size, and the incidence of adverse effects. The results demonstrated a significantly superior improvement in pigmentation for the Tacrolimus group, with the mean pigmentation index increasing from 59.37 to 156.72 Melanin units, a substantial gain over the Desonide group's increase from 61.78 to 114.92 Melanin units (p < 0.001). Furthermore, 73.3% of patients in the Tacrolimus group achieved a good to very good response in terms of lesion size reduction, markedly surpassing the 16.7% in the Desonide group (p < 0.001). Adverse events associated with Tacrolimus 0.03% were mild and transient, primarily involving itching, stinging, and mild burning in 13.33% of patients, none of whom discontinued treatment. In contrast, the Desonide group experienced telangiectasia in one case. These findings suggest that topical Tacrolimus 0.03% is an effective and safe treatment option for facial pityriasis alba, offering a valuable alternative to topical corticosteroids, particularly for sensitive facial skin and for pediatric and adolescent populations, given its good tolerability and minimal side effects. The study contributes important evidence for clinical practice, supporting the broader adoption of Tacrolimus as a first-line treatment in specific contexts.